Intellia Therapeutics NASDAQ: NTLA is preparing for a potential U.S. launch of its hereditary angioedema gene-editing therapy, lonvo-z, while advancing late-stage studies in transthyretin amyloidosis, company executives said during a Jefferies fireside chat.
The Food and Drug Administration is reviewing the lonvo-z biologics license application under priority review, with a decision date of March 10, 2027, Jefferies analyst Maury Raycroft said. CEO John Leonard said the agency has indicated that, so far, it does not see a need for an advisory committee meeting.
“Nothing has been out of the ordinary,” Leonard said of the review. He added that the company participated in an FDA manufacturing pilot program and that the review has been going well.
Launch planning and payer coverage
Lonvo-z is designed as a one-time therapy for hereditary angioedema, or HAE. Leonard said every patient across the phase 1, 2 and 3 studies had discontinued long-term preventive therapy. He also said use of on-demand therapy had fallen substantially from pretreatment levels.
One patient continued to have attacks, though at a reduced rate, Leonard said. He said the patient’s treating physician and others examining the case believe the patient may have another condition in addition to HAE.
CFO Edward Dulac said the company has more than four years of follow-up data on the protein kallikrein in early patients and plans to continue monitoring them. Leonard said Intellia had not seen a patient lose the pharmacologic effect across its HAE and TTR programs, with follow-up extending to six years in the earlier-started TTR program.
Intellia has not disclosed a price for lonvo-z. Dulac declined to provide manufacturing cost details but said the synthetic therapy would be a high-margin product.
If the treatment is approved, Dulac said payer coverage would be the main factor limiting the speed of its launch. He expects patients to be managed through medical exceptions during the first three months, with initial contracts, treatments and revenue recognition beginning in the following three months. The company hopes to have coverage for many HAE patients by month nine, he said.
In market research involving about 150 patients, nearly 70% indicated they would be willing to see their physician within six months of approval to discuss options including lonvo-z, Dulac said. He cautioned that the company does not know precisely how adoption would unfold.
Outside the U.S., Dulac said Intellia is considering options including licensing and distribution arrangements, but its immediate focus is on the domestic launch. He also said the company understands cell and gene therapies to be excluded from most-favored-nation pricing considerations.
ATTR trials and finances
Intellia is also studying nex-z in phase 3 trials for transthyretin amyloidosis, or ATTR, affecting the heart and nerves. Leonard said sites have been restarting after a clinical hold was lifted, with some international sites taking longer to process study amendments. Patients remained in the study and continued contributing endpoints during the hold, he said.
The company recently completed enrollment in MAGNITUDE-2, its ATTR polyneuropathy study. Leonard declined to give a final enrollment figure but said it was reasonable to think of an overage of roughly 10% to 15% above the target of approximately 60 patients. A nine-month interim analysis is an option, he said, but is not currently planned.
For the cardiomyopathy trial, Leonard declined to provide an updated enrollment figure. He said Intellia was ahead of schedule and may adjust the study as it evaluates information from other trials in the field.
Dulac said Intellia had approximately $615 million in cash and cash equivalents as of the third quarter and enough cash to extend into 2028. That guidance does not assume revenue or cash contribution from lonvo-z or additional debt tranches, he said. Future financing needs will depend in part on the therapy’s performance if approved.
About Intellia Therapeutics (NASDAQ:NTLA)
Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing treatments for serious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company uses CRISPR/Cas9 technology to make targeted changes to DNA. Its research includes in vivo therapies, which are designed to edit genes inside a patient's body, and ex vivo approaches, which involve modifying cells outside the body before they are returned to the patient. Intellia's investigational programs have included treatments for transthyretin amyloidosis and hereditary angioedema.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.